论文部分内容阅读
目的探讨依达拉奉联合低分子肝素治疗急性脑梗死临床效果。方法选择我院2009年3月至2011年3月急性脑梗死患者200例,上述患者随机分为观察组和对照组。两组均给予常规治疗,对照组同时给予低分子右旋糖酐及复方丹参注射液,观察组给予依达拉奉及低分子肝素。观察两组治疗效果和神经功能缺损评分情况。结果观察组治疗神经功能缺损评分显著低于对照组治疗后,差异有统计学意义(P<0.05);观察组总有效率显著高于对照组,差异有统计学意义(P<0.05)。结论依达拉奉联合低分子肝素能够显著提高急性脑梗死患者治疗效果,较好的改善神经功能缺损症状,值得借鉴。
Objective To investigate the clinical efficacy of edaravone combined with low molecular weight heparin in the treatment of acute cerebral infarction. Methods 200 cases of acute cerebral infarction in our hospital from March 2009 to March 2011 were selected. The above patients were randomly divided into observation group and control group. Both groups were given routine treatment, while the control group given low molecular dextran and compound Salvia injection, the observation group were given edaravone and low molecular weight heparin. The therapeutic effect and neurological deficit score of the two groups were observed. Results The score of neurological deficit in observation group was significantly lower than that in control group after treatment (P <0.05). The total effective rate in observation group was significantly higher than that in control group (P <0.05). Conclusion Edaravone combined with low molecular weight heparin can significantly improve the therapeutic effect of patients with acute cerebral infarction, and better to improve the symptoms of neurological deficit, it is worth learning from.